shutterstock_1492661771_ricochet64-1
ricochet64 / Shutterstock.com
2 November 2021Big Pharma

English High Court denies Mylan a stay in Neurim litigation

Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
26 May 2022   The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.
Americas
8 December 2020   Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.
Big Pharma
25 January 2022   Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.

More on this story

Europe
26 May 2022   The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.
Americas
8 December 2020   Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.
Big Pharma
25 January 2022   Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.

More on this story

Europe
26 May 2022   The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.
Americas
8 December 2020   Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.
Big Pharma
25 January 2022   Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.